Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Summary of day two of the European Meeting of ISMPP: “Doing ...

Ryan Woodrow continues his overview of the European Meeting of ISMPP, with a summary of day two. It is essential that medical publication professionals follow guidelines and best practice to ensure that the industry’s reputation for...

Articles

mHealth Monthly Mashup: Release 18.0 – mobile health snapsho...

This month’s mashup takes a photo of the current mobile health landscape and peers at the compelling possibilities. Like Alice grabbed by the Red Queen in Through the Looking-Glass, healthcare players from professionals to...

Articles

How is European pharma responding to stricter transparency l...

As the tough promotional transparency laws in the US reach the European shores, Cegedim Relationship Management finds out how prepared pharma organisations are. The pharmaceutical, medical device and biotech industries are currently witnessing the rise of transparency...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital